Virginia Retirement Systems Et Al Tcr2 Therapeutics Inc. Transaction History

Virginia Retirement Systems Et Al

  • $10.1 Billion
  • Q3 2023

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 21, 2021
SELL
$8.44 - $18.35 $117,316 - $255,065
-13,900 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$16.41 - $24.71 $60,717 - $91,427
3,700 Added 36.27%
13,900 $228,000
Q1 2021

Apr 30, 2021
BUY
$20.38 - $34.07 $207,876 - $347,514
10,200 New
10,200 $225,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email